NICE Wants Cosmetic Providers to Screen for BDD and Refer Rather Than Operate
- NICE published draft guidance on 17 September 2026 covering obsessive-compulsive disorder and body dysmorphic disorder, aimed at earlier identification. Consultation runs until 21 October 2026. OCD affects an estimated 1.2% of the population and BDD around 2% of adults.
- Healthcare professionals providing cosmetic treatments, including surgeons, dentists and dermatologists, would be advised to ask structured questions about appearance-related concerns and document the findings. Where responses indicate possible BDD, the draft recommends referral for specialist assessment rather than proceeding with the procedure.
- NICE cites a 2024 systematic review and meta-analysis estimating that 18.6% of people attending aesthetic and reconstructive plastic surgery services had clinically significant BDD symptoms, against roughly 2% in the wider adult population. The committee noted cosmetic procedures rarely improve the underlying condition and may worsen symptoms.
- The draft also replaces the fixed stepped pathway for OCD with a matched care approach, offering treatments from the outset based on clinical need, treatment history and preference. For children and young people it recommends family-based cognitive behavioural therapy. Clinicians are advised to consider assessing for OCD or BDD in people with depression, anxiety, autism or ADHD.
Clinical read
Coverage will treat this as a mental health guideline. One recommendation reaches directly into a commercial market and tells its providers to turn business away.
- The cosmetic screening recommendation has a revenue consequence. If 18.6% of people presenting to aesthetic and reconstructive services carry clinically significant BDD symptoms, and providers are advised to refer rather than proceed, a meaningful share of a self-pay market moves into psychiatric referral. Aesthetics operators will read that paragraph before any other.
- Matched care dismantles the stepped pathway. Replacing a fixed sequence with treatment chosen from the outset removes the requirement to fail cheaper interventions first. That changes where psychological therapy and pharmacotherapy sit across all 2 conditions covered, and in time what commissioners fund at each stage.
- The screening triggers widen the identified population. Assessing for OCD or BDD in people with depression, anxiety, autism or ADHD reaches across 4 large existing caseloads. Against a baseline of 1.2% for OCD, systematic case-finding in those groups will raise diagnosed prevalence before any treatment capacity is added.